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Abstract 
 
Acute kidney injury (AKI) is defined by the KDIGO definition into 3 stages on basis of an 
increase of serum creatinine or a period of oliguria. AKI is defined as rapid reversal when the 
episode is 48 hours or less. When AKI persists for 7 days or longer, the term acute kidney 
disease (AKD) is used. Subclinical AKI is defined by increased concentration of an AKI 
biomarker, without meeting the KDIGO definition for AKI. In contrast to this, functional AKI is 
defined by the KDIGO definition, while the AKI biomarker concentration is not increased. AKI 
is multifactorial and heterogeneous and occurs in half of ICU patients as defined by the 
current KDIGO definition for AKI.  
In this review, we specifically describe the epidemiology of cardiac surgery associated AKI 
(CSA-AKI), and describe the role of scoring systems and specific AKI biomarkers. 
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Introduction 
Acute kidney injury (AKI) is a frequent occurring complication in ICU patients (1). The 
pathophysiology of AKI in this specific setting is often multifactorial and dependent on the 
baseline characteristics of the patients and specific procedures during or after surgery. Here 
we will describe the epidemiology of AKI occurring after cardiac surgery as a typical example 
of postoperative AKI. The Acute Disease Quality Initiative (ADQI) proposed the terminology 
cardiac surgery associated AKI (CSA-AKI) for this (2). Since, cardiac dysfunction is considered 
the main contributing cause of decline in kidney function, CSA-AKI is classified as acute 
cardiorenal syndrome type I (CRS type 1) (3).  
 
Definition of AKI 
CSA-AKI has been defined by at least 35 different definitions in medical literature (2). 
Previously, this condition was often referred to with the non-uniform definition “worsening 
renal function” (WRF). Since 2012, the consensus definition of AKI is the modified version of 
the RIFLE and AKIN classifications as proposed by the Kidney Disease: Improving Global 
Outcomes (KDIGO) Acute Kidney Injury Working Group (4). KDIGO defines and stages 
occurrence of AKI on an acute increase of serum creatinine or a period of oliguria (table 1). 
More recently, ADQI defined rapid reversal of AKI by an episode of AKI which lasts 48 hours 
or less, and Acute Kidney Disease (AKD) by a duration of AKI of 7 days or more (table 2)(5). 
CSA-AKI typically occurs after cardiac surgery, but may already begin before this procedure, 
i.e. in patients who present with cardiogenic shock or after contrast administration. Early 
CSA-AKI occurs within 7 d after cardiac surgery, and is more likely induced by cardiac 
surgery, while late AKI occurs between 7 and 30 days after cardiac surgery and has only an 
association with the preceding cardiac surgery (2).  
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Prediction of AKI: scoring systems  
Several scores have been developed to predict CSA-AKI. Examples of these are the Cleveland 
clinic score (6), Mehta score (7), Ng score (8), the Murphy score (9), and the CRATE score 
(10). The first two scores were developed in US populations, with the latter three in 
Australian, UK and Spanish populations respectively. Older scores often predict non-
consensus definitions of AKI or use of renal replacement therapy (RRT), while more recent 
scores use the KDIGO consensus or its variants (RIFLE or AKIN) as an endpoint. The 
discrimination of these scores is reasonably good, with area under the receiver operating 
characteristic curve values generally in the range of 0.75-0.8, when compared between 
discovery and validation cohorts or when applied in different cohorts or settings (11, 12).  
 
 
Functional AKI and Damage: the role of new kidney biomarkers 
The KDIGO definition of AKI is based on a decline of glomerular filtration rate (GFR) with 
resultant increase of serum creatinine or a period of oliguria. As such, this definition only 
captures a decline in GFR, and not true damage to the kidneys. In a normal scenario, this 
functional decline of kidney function is preceded by stress or damage to the kidneys (figure 
1) which can be demonstrated by increased concentration of specific kidney biomarkers 
(13). Subclinical AKI occurs when a patient has a positive biomarker reading without meeting 
the KDIGO criteria for AKI. Similar to AKI defined by KDIGO, this condition is also reported 
with worse clinical outcomes (14, 15). At present over a dozen of AKI biomarkers have been 
evaluated in in-vitro and clinical studies. Of these, neutrophil gelatinase associated lipocalin 
(NGAL) (16, 17) and the combination biomarker test tissue inhibitor of metalloproteinases-2 
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(TIMP-2) and insulin-like growth factor-binding protein 7 (IGFBP7) (NephroCheck®) are 
available for clinical use (18–22). Increased concentrations of biomarkers indicate more 
damage, which led to the CSA-NGAL score as a tool to monitor damage to the tubules and 
guide therapeutic and preventive actions (23). NGAL has been studied most in this setting, 
and its diagnostic ability for CSA-AKI is generally good (17), however, there is considerable 
variation and some studies showed low predictive value for this biomarker (24). Clinical 
experience showed good discriminative ability for the NephroCheck to diagnose CSA-AKI. 
However, the number of patients studied in this specific setting is still limited. Biomarkers 
can also be used for risk stratification. Recently, a pilot study demonstrated that application 
of a bundle of AKI measures in a cohort of cardiac surgery patients at increased risk for AKI, 
as defined by the NephroCheck, resulted in less AKI (25). 
Functional AKI is often referred to when patients meet the KDIGO criteria for AKI but 
without increased concentration of kidney damage biomarkers (24).  
 
Epidemiology and outcomes of AKI 
 
Two recent meta-analyses found that the incidence of CSA-AKI defined by RIFLE, AKIN and 
KDIGO definitions was 22% (26, 27). The majority of CSA-AKI patients will only have mild AKI 
with maximum severity stage 1 (14-18% of patients or 61-81% of AKI patients); stage 2 
occurs in 17-20% of patients (17-19.9% of AKI patients), and 12-16% will have stage 3 (12.1-
15.8 of AKI patients). RRT is used in 2.3% to 3.1% of patients (10-14% of AKI patients).  
CSA-AKI is associated with increased costs and use of resources as indicated by a longer 
length of hospital stay in CSA-AKI patients compared to no AKI patients (15 d vs. 10.5 d). 
Increasing severity of AKI is associated with increased duration of hospital stay (stage 1: 14 
d, stage 2: 18 d, and stage 3: 26.3 d).  
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CSA-AKI patients experience a short-term mortality of 10% compared to 1.7% of patients 
without AKI (OR = 8.52, 95%CI = 8.00 to 9.07), with a stepwise increase in short-term 
mortality with increasing AKI stage (stage 1: 5.7%, stage 2: 16.2%, and stage 3: 36.7%). Long-
term mortality is also increased in CSA-AKI patients compared to CS patients without AKI 
(30% vs. 11.9%). After adjustment for other covariates that may explain mortality, there is a 
proportional increased risk for mortality to severity stages of AKI (28, 29). While some found 
this association between CSA-AKI and mortality persist for over a 10-y follow up period, a 
large study in Uruguay found that after 5-y follow up this association disappeared (29).  
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Practice Points 
 
• AKI is defined by the KDIGO definition into 3 severity stages, and based on an 
increase of serum creatinine or an episode of oliguria 
• Rapid reversal is defined by an AKI period of 48 h or less 
• Acute Kidney Disease is defined by an episode of 7 days or longer 
• AKI occurs in half of ICU patients, and 1 in 5 of cardiac surgery patients 
• RRT is used in 2.3-3.1% of cardiac surgery patients 
• (CSA-)AKI is associated with mortality after adjustment for covariates 
 
 
 
Research Agenda 
• To better characterize risk factors and biomarkers for development of AKI 
• To better characterize risk factors and biomarkers for long-term outcomes after AKI 
• More studies are warranted on the use of biomarkers for risk stratification in therapy 
for AKI prevention. 
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Tables 
 
Table 1: The Kidney Disease: Improving Global Outcomes (KDIGO), diagnosis and grading 
system for Acute Kidney Injury (4). 
 
a) AKI is defined by either an increase of serum creatinine or an episode of oliguria: 
 Increase of serum creatinine ≥ 0.3 mg/dL (26.5 µmol/L) within 48-hours, or 
 Increase of serum creatinine by ≥1.5-fold above baseline, know or assumed to have 
occurred within 7 days, or 
 Urine volume < 0.5 mL/kg/h for 6 hours. 
b) AKI severity is staged by the worst of either serum creatinine changes or oliguria 
Stage Serum creatinine Urine output 
1 ≥ 1.5 to 1.9 times baseline 
OR 
> 0.3 mg/dL (26.5 µmol/L) increase 
<0.5 mL/kg/h for 6-12 h 
2 ≥ 2.0 to 2.9 times baseline <0.5 mL/kg/h for ≥12 h 
3 ≥ 3.0 times baseline 
OR 
Increase of serum creatinine to ≥ 4.0 mg/dL 
(353.6 µmol/L) 
OR 
RRT 
OR  
In patients <18y, decrease of eGFR to <35 
mL/min per 1.73m2 
<0.3 mL/kg/h for ≥ 24 h 
OR  
Anuria for ≥12 h 
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Table 2: Nomenclature used in Acute Kidney Injury (4, 5) 
 
Rapid reversal Acute Kidney Injury Duration of ≤ 48h 
Acute Kidney Injury Duration of ≤ 7 days 
Acute Kidney Disease Duration of > 7 days and < 90 days 
Functional Acute Kidney Injury KDIGO positive 
Biomarker negative 
Subclinical Acute Kidney Injury KDIGO negative  
Biomarker positive 
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Figures  
 
Figure 1: Transition of normal kidney function to acute kidney injury (after (13)) 
 
Legend: GFR = glomerular filtration rate, KDIGO = kidney disease: improving global outcomes 
criteria and stages for acute kidney injury, RRT = renal replacement therapy 
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